These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36570409)

  • 1. Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia.
    Low JL; Lim E; Bharwani L; Wong A; Wong K; Ow S; Lim SE; Lee M; Choo J; Lim J; Chan G; Walsh RJ; Muthu V; Ngoi N; Chong W; Tan SH; Lee SC
    Ther Adv Med Oncol; 2022; 14():17588359221139678. PubMed ID: 36570409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.
    Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC
    Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy.
    Akdag G; Dogan A; Yildirim S; Kinikoglu O; Mokresh ME; Alomari O; Turkoglu E; Isik D; Sürmeli H; Basoglu T; Sever ON; Odabas H; Yildirim ME; Turan N
    Cureus; 2024 Jun; 16(6):e63362. PubMed ID: 39070363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
    Smyth EN; Beyrer J; Saverno KR; Hadden E; Abedtash H; DeLuca A; Lawrence GW; Rybowski S
    Drugs Real World Outcomes; 2022 Dec; 9(4):681-693. PubMed ID: 36097254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
    Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M
    JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
    Tian Q; Gao H; Zhou Y; Yang J
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer.
    Sathe C; Accordino MK; DeStephano D; Shah M; Wright JD; Hershman DL
    Breast Cancer Res Treat; 2023 Jul; 200(1):85-92. PubMed ID: 37157005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study.
    Püsküllüoğlu M; Ziobro M; Lompart J; Rudzińska A; Zemełka T; Jaworska J; Ochenduszko S; Grela-Wojewoda A
    Cancers (Basel); 2024 Aug; 16(16):. PubMed ID: 39199665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective registry of patients with locally advanced/metastatic HR
    Chavarría Piudo N; Blancas I; González Flores E; Henao Carrasco F; López Álvarez P; Morales Pancorbo D; Gámez Casado S; Lomas Garrido MC; Rodríguez García JM; Martínez Guisado A; Sánchez Vega A; Ruíz Borrego M
    Clin Transl Oncol; 2024 Dec; 26(12):3131-3141. PubMed ID: 38831191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
    Martin JM; Handorf EA; Montero AJ; Goldstein LJ
    Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
    Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD
    Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.
    Petracci F; Abuin GG; Pini A; Chacón M
    Ecancermedicalscience; 2020; 14():1058. PubMed ID: 32582373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
    Beddok A; Mouren V; Cottu P; Laki F; Fourquet A; Kirova Y
    Int J Cancer; 2023 Oct; 153(7):1386-1396. PubMed ID: 37381597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis.
    Kubeczko M; Polakiewicz-Gilowska A; Świderska K; Leśniak A; Mianowska-Malec M; Łanoszka B; Chomik K; Grandys B; Lisovska N; Bobek-Billewicz B; Chmielik E; Jarząb M
    Front Oncol; 2024; 14():1408664. PubMed ID: 38912058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report:
    Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
    Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
    Zattarin E; Mariani L; Menichetti A; Leporati R; Provenzano L; Ligorio F; Fucà G; Lobefaro R; Lalli L; Vingiani A; Nichetti F; Griguolo G; Sirico M; Bernocchi O; Marra A; Corti C; Zagami P; Agostinetto E; Jacobs F; Di Mauro P; Presti D; Sposetti C; Giorgi CA; Guarneri V; Pedersini R; Losurdo A; Generali D; Curigliano G; Pruneri G; de Braud F; Dieci MV; Vernieri C
    Ther Adv Med Oncol; 2023; 15():17588359231204857. PubMed ID: 38130467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
    Cook MM; Al Rabadi L; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
    Oncologist; 2021 Feb; 26(2):101-106. PubMed ID: 33230905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
    Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
    Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.